Rennova Health, Inc., a company based in West Palm Beach, Florida, operates within the Health Care sector, specifically under the Health Care Providers & Services industry. As of March 8, 2026, Rennova Health’s stock, traded on the OTC Bulletin Board under the ticker symbol RNVA, was valued at $0.0001. This price point represents both the 52-week high and low, indicating a period of remarkable stability—or stagnation—in the company’s market valuation. Over the past year, the share price has remained unchanged, reflecting a lack of significant price movement and suggesting limited liquidity and investor interest.
The company’s market capitalization stands at approximately $4,305,132 USD, a figure that underscores its relatively modest size within the healthcare sector. The price-to-earnings ratio, recorded at -0.014, further highlights the challenges Rennova Health faces in demonstrating profitability or growth potential to investors. This negative ratio often signals that the company is not currently generating earnings, which can be a deterrent for potential investors seeking positive returns.
Rennova Health specializes in providing a range of healthcare-related products and services to healthcare providers across the United States. Despite its specialized focus, the company’s financial metrics and stock performance suggest that it has struggled to capture significant market attention or drive substantial growth. The absence of notable price fluctuations over the past year indicates a static valuation, with no evidence of upward or downward momentum.
Historically, the company’s stock briefly surpassed its 200-day moving average on April 19, 2025, as noted in recent coverage. However, this momentary achievement did not translate into sustained price action or increased investor interest. The lack of subsequent price movement suggests that the brief surge was an anomaly rather than a sign of underlying strength or potential for growth.
In summary, Rennova Health, Inc. remains a small player in the healthcare sector, with a static market valuation and limited investor interest. The company’s financial metrics, including its negative price-to-earnings ratio and unchanged share price over the past year, reflect the challenges it faces in demonstrating growth and profitability. As it continues to operate within the competitive healthcare industry, Rennova Health will need to address these challenges to attract investor attention and drive future growth.
